Response to Lavin et al (2025)’s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

HOME
>
論文・技術情報
>
Response to Lavin et al (2025)’s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

アブストラクト
ジャーナル名	The Journal of investigative dermatology
Pubmed追加日	2025/7/3
投稿者	James, Mariel L; Pink, Andrew E; Woolf, Richard T; Batty, Patrick; Mahil, Satveer; Smith, Catherine H; Whittaker, Sean; Langan, Sinead M
組織名	St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundational Trust,;London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;London, United Kingdom; King's College London, London, United Kingdom.;London, United Kingdom; King's College London, London, United Kingdom. Electronic;address: sean.whittaker@kcl.ac.uk.;London, United Kingdom; London School of Hygiene and Tropical Medicine, London,;United Kingdom.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/40602644/